# LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

> **NCT01085136** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1154 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Investigator´s choice of chemotherapy
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT01085136
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-10
- **Final completion:** 2016-01
- **Target enrollment:** 1154 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085136, "LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01085136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*